Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Feb 10;8(3):128-42.
doi: 10.4253/wjge.v8.i3.128.

Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy

Domenico Viterbo  1 , Valerie Gausman  1 , Tamas Gonda  1
Affiliations
Review

Diagnostic and therapeutic biomarkers in pancreaticobiliary malignancy

Domenico Viterbo et al. World J Gastrointest Endosc. .

Abstract

Pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CCA) are two malignancies that carry significant morbidity and mortality. The poor prognoses of these cancers are strongly related to lack of effective screening modalities as well as few therapeutic options. In this review, we highlight novel biomarkers that have the potential to be used as diagnostic, prognostic and predictive markers. The focus of this review is biomarkers that can be evaluated on endoscopically-obtained biopsies or brush specimens in the pre-operative setting. We also provide an overview of novel serum based markers in the early diagnosis of both PDAC and CCA. In pancreatic cancer, the emphasis is placed on prognostic and theranostic markers, whereas in CCA the utility of molecular markers in diagnosis and prognosis are highlighted.

Keywords: Biological markers; Biopsies; Brush specimens; Cholangiocarcinoma; Diagnostic; Pancreatic cancer; Predictive; Prognostic.

PubMed Disclaimer

References

    1. Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144:1252–1261. - PMC - PubMed
    1. Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548–4554. - PMC - PubMed
    1. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–1825. - PubMed
    1. Alvaro D, Cardinale V. Molecular profiling. In: Herman JM, Pawlik TM, Thomas Jr, editors. CR, editors. Biliary Tract and Gallbladder Cancer: A Multidisciplinary Approach. 2nd ed. Springer; 2014. pp. 99–117.
    1. Reddy SB, Patel T. Current approaches to the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep. 2006;8:30–37. - PubMed

LinkOut - more resources